MedTrace Logo

Treatment of Recurrent GBM With APG-157 Via Expanded Access

NCT05551013 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-08-09

No results posted yet for this study

Summary

This expanded access request will evaluate APG-157, a botanical drug under development for other cancers, as potential treatment for recurrent Glioblastoma multiforme (GBM) patients.

Conditions

Interventions

DRUG

APG-157

APG-157 is an orally administered drug encased in a hydrogel pastille. Arms: * Ongoing Stupp protocol (will receive concurrent TMZ + APG-157) * Progression post TMZ (will receive APG-157 only) * Ongoing Optune (will receive concurrent Optune + APG-157) * Progression post Optune (will receive APG-157 only)

Sponsors & Collaborators

  • Aveta Biomics, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05551013 on ClinicalTrials.gov